934544-42-0

Basic information

• Product Name: diclofenac didecyldimethylammonium salt
• Synonyms: diclofenac didecyldimethylammonium salt
• CAS NO: 934544-42-0
• Molecular Weight: 621.775
• Mol File: 934544-42-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: diclofenac didecyldimethylammonium salt(CAS DataBase Reference)
• NIST Chemistry Reference: diclofenac didecyldimethylammonium salt(934544-42-0)
• EPA Substance Registry System: diclofenac didecyldimethylammonium salt(934544-42-0)

Safety Data

• Hazardous Substances Data: 934544-42-0(Hazardous Substances Data)

Upstream product

• 15307-79-6 diclofenac sodium 
• 2390-68-3 N,N-didecyl-N,N-dimethylammonium bromide 
• 7173-51-5 didecyldimethylammonium chloride 

Relevant articles and documents

Ionic Liquid Forms of Weakly Acidic Drugs in Oral Lipid Formulations: Preparation, Characterization, in Vitro Digestion, and in Vivo Absorption Studies

This study aimed to transform weakly acidic poorly water-soluble drugs (PWSD) into ionic liquids (ILs) to promote solubility in, and the utility of, lipid-based formulations. Ionic liquids (ILs) were formed directly from tolfenamic acid (Tolf), meclofenamic acid, diclofenac, and ibuprofen by pairing with lipophilic counterions. The drug-ILs were obtained as liquids or low melting solids and were significantly more soluble (either completely miscible or highly soluble) in lipid based, self-emulsifying drug delivery systems (SEDDS) when compared to the equivalent free acid. In vivo assessment of a SEDDS lipid solution formulation of Tolf didecyldimethylammonium salt and the same formulation of Tolf free acid at low dose (18 mg/kg, where the free acid was soluble in the SEDDS), resulted in similar absorption profiles and overall exposure. At high dose (100 mg/kg), solution SEDDS formulations of the Tolf ILs (didecyldimethylammonium, butyldodecyldimethylammonium or didecylmethylammonium salts) were possible, but the lower lipid solubility of Tolf free acid dictated that administration of the free acid was only possible as a suspension in the SEDDS formulation or as an aqueous suspension. Under these conditions, total drug plasma exposure was similar for the IL formulations and the free acid, but the plasma profiles were markedly different, resulting in flatter, more prolonged exposure profiles and reduced Cmax for the IL formulations. Isolation of a weakly acidic drug as an IL may therefore provide advantage as it allows formulation as a solution SEDDS rather than a lipid suspension, and in some cases may provide a means of slowing or sustaining absorption. The current studies compliment previous studies with weakly basic PWSD and demonstrate that transformation into highly lipophilic ILs is also possible for weakly acidic compounds.